Loading stock data…
ADPT
$13.54-0.27 (-1.96%)
Market ClosedLast close May 11
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Adaptive Biotechnologies Corporation in the Healthcare sector is trading at $13.54. The stock is currently 35% below its 52-week high of $20.76, remaining 9.8% below its 200-day moving average. Technical signals show neutral RSI of 44 and bearish MACD signal, explaining why ADPT maintains its current current market pressure. The Whystock Score of 35/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 44) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$13.54
Potential Upside
5%
Whystock Fair Value$14.22
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.19B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.30
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-55.41%
Volume
Today's trading volume
1.40M
Recent News
Assessing Adaptive Biotechnologies (ADPT) Valuation After Strong MRD Growth And Raised Full Year Guidance
Adaptive Biotechnologies (ADPT) has attracted fresh attention after reporting first quarter 2026 results, along with higher full year revenue guidance for its Minimal Residual Disease business, supported by growing clonoSEQ adoption and broader payor coverage. See our latest analysis for Adaptive Biotechnologies. Despite the raised MRD guidance and solid first quarter update, Adaptive Biotechnologies' share price has been volatile, with a 7.98% 1 month share price gain but a year to date...
Adaptive Biotechnologies (ADPT) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Adaptive Biotechnologies (ADPT) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Adaptive Biotechnologies Q1 Earnings Call Highlights
Adaptive Biotechnologies (NASDAQ:ADPT) reported first-quarter 2026 results that executives said showed “accelerating momentum” in measurable residual disease (MRD) testing, alongside continued operational efficiency gains and a higher full-year MRD revenue outlook. MRD growth drives revenue as comp
Adaptive Biotechnologies (ADPT) Reports Q1 Loss, Beats Revenue Estimates
Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of +16.13% and +14.61%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Adaptive Biotechnologies' Chief Operating Officer Sold Over 19,000 Company Shares. Here's What That Means for Investors.
This immune diagnostics innovator reported a notable insider sale as it advances platforms for disease detection and monitoring.